<DOC>
	<DOC>NCT02941783</DOC>
	<brief_summary>The objective in this study is collecting post-marketing information on the safety and efficacy of Kovaltry under the routine clinical practice.</brief_summary>
	<brief_title>Drug Use Investigation of Kovaltry in Hemophilia A Patients</brief_title>
	<detailed_description>This company-sponsored study is a single-arm, prospective, observational study in hemophilia A patients administered Kovaltry. 200 cases will be planned to be registered as safety analysis set in three-year period. Within 200 cases, 50 cases less than 12 years old will be planned to be registered. Target population are all hemophilia A patients. The treatment should be performed based on the product label in Japan. The standard observation period is two years.</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male and female hemophilia A patients. Patients for whom the decision to treat with Kovaltry was determined prior to enrollment in the study. Patients participating in an investigational program with interventions outside of routine clinical practice. Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kovaltry</keyword>
	<keyword>hemophilia A</keyword>
	<keyword>Japan</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>